GAITHERSBURG, Md., May 7, 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company
advancing protein-based vaccines with its Matrix-M™ adjuvant, today
announced it will report its first quarter 2024 financial results
and operational highlights at 8:30 a.m.
Eastern Time (ET) on Friday, May 10,
2024. Details of the event and replay are as follows:
Conference call
details:
|
|
Date:
|
May 10, 2024
|
Time:
|
8:30 a.m. U.S.
ET
|
URL to register
phone:
|
https://emportal.ink/3VNP8J5
|
Dial-in number:
|
(888) 664-6383
(Domestic) or
|
|
(+1) (416) 764-8650
(International)
|
Webcast:
|
ir.novavax.com/events
|
- Participants can join the conference call without operator
assistance by registering and entering their phone number with the
above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the
call by an Operator and will be prompted to request to join
the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
Replay
details:
|
|
Date:
|
Available starting at
11:30 a.m. ET, May 10, 2024, until 11:59 p.m. U.S. ET, May 17,
2024
|
Dial-in
number:
|
(888) 390-0541
(Domestic) or
|
|
(+1) (416) 764-8677
(International)
|
Passcode:
|
414036#
|
Webcast:
|
ir.novavax.com/events,
until June 10, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by
discovering, developing and commercializing innovative
vaccines to help protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S.,
offers a differentiated vaccine platform that combines a
recombinant protein approach, innovative nanoparticle technology
and Novavax's patented Matrix-M adjuvant to enhance the immune
response. The Company's portfolio includes its COVID-19 vaccine and
its pipeline includes a vaccine for COVID-19 and influenza
combined. In addition, Novavax's adjuvant is included in
the University of Oxford and Serum Institute
of India's R21/Matrix-M malaria vaccine. Please
visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2024-financial-results-and-operational-highlights-on-may-10-2024-302138130.html
SOURCE Novavax, Inc.